The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

As the S&P 500 reaches new highs amid optimism over trade deals and corporate earnings, investors are closely watching the tech sector, which continues to drive market momentum despite concerns about ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...